GLP-1 & compounded medication availability in New York (2026)
New York is the largest market this page family has reached, and its file is quieter than its size suggests: our research pass found no New York-specific published position on any of the ten product lines below. What New York asks for is operational: an out-of-state pharmacy registers with the state before shipping in, and a real telehealth evaluation stands behind every prescription. Both requirements are cited below, next to the full ten-line matrix.
Every line, one New York answer each
| Product line | Available in New York? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | From partner pharmacies registered with New York as nonresident establishments. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Same registration-backed path as the row above. |
| NAD+ | Yes | 8–10 business days | No New York-specific caveat surfaced. |
| Sermorelin | Yes | 8–10 business days | Ships on the ordinary ordering flow. |
| Glutathione | No | N/A | A catalog gap, not a New York one. We do not offer it in any state. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; its federal record sits just below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable; section below has its record. |
| KPV | No | N/A | We compound peptide lines as injectables only, and KPV is not one. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; federal facts in its section. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable with a federal record all its own, below. |
The two No rows above would be the easiest things on this page to hide. They stay, because an availability page that omits what’s missing is an ad. New York facts reviewed November 16, 2026.
Research peptides shipped to New York: the full record
New York’s regulators have published nothing peptide-specific that this research pass could locate, so the five sections below are governed by the one federal record this whole page family shares. OrderlyMeds compounds BPC-157, TB-500, Epitalon and MOTS-c as injectables for New York addresses; KPV is outside our formulary in every state. Each line’s section states its own federal facts, and they are not interchangeable.
BPC-157 in New York
Dispensed to New York patients as a compounded injectable on a patient-specific prescription. Before ordering, read its federal record:
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in New York
In the New York catalog as a compounded injectable. These are the facts attached to it:
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in New York
Not something we ship to New York, or anywhere. OrderlyMeds compounds its peptide lines as injectables, and KPV is not among them.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in New York
Available to New York patients as a compounded injectable under a patient-specific prescription. Its record follows:
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in New York
Ships to New York as a compounded injectable. Its federal history is distinct from the four lines above, so read it on its own terms.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What New York’s pharmacy regulators say about compounded medications
New York’s pharmacy profession answers to the State Education Department’s Office of the Professions, and its file on the medications this page tracks is notably general: the rules that matter are the ones that apply to every prescription drug, not special carve-outs. Four cited facts carry this section.
As of November 16, 2026, New York’s pharmacy regulators have published no rule or guidance specific to compounded GLP-1 medications or compounded peptides; pharmacy compounding in New York is governed by the general framework of Education Law Article 137. Source: NYSED Office of the Professions — Education Law Article 137.
Out-of-state pharmacies that ship, mail, or deliver prescription drugs to patients in New York must first register with the State Education Department as nonresident establishments under Education Law §6808-b, maintaining home-state good standing and a registered agent in the state. Source: NY Education Law §6808-b.
New York permits prescribing on the basis of a telehealth encounter under Public Health Law Article 29-G; the state’s prior in-person-evaluation requirement attaches to controlled substances, with an express telehealth exception consistent with federal rules. Source: Center for Connected Health Policy (CCHP) Policy Finder — New York.
New York law separately requires sterile-drug outsourcing facilities to hold federal registration and bars them from compounding drugs that are essentially copies of approved products — the state-law mirror of the federal 503B limits. Source: NY Education Law §6831.
In practice a New York order looks like any other OrderlyMeds order: an online eligibility check, an evaluation by a New York-licensed provider, and fulfillment by a partner pharmacy holding the §6808-b registration. None of the ten lines on this page is a controlled substance, so the in-person-first rule New York applies there never enters the picture. Pricing is national, so New York pays what every state pays.
New York availability FAQs
Is compounded semaglutide available in New York?
Yes. OrderlyMeds ships compounded semaglutide to New York addresses from partner pharmacies registered with the state as nonresident establishments, under patient-specific prescriptions. New customers start at $74/month for the first two months.
Do I need an in-person doctor visit to get started in New York?
No. New York’s in-person-evaluation rule applies to controlled substances, and none of the ten lines on this page is one. A telehealth evaluation by a New York-licensed provider is the standard path, and the regulator section above carries the citation.
Can I get BPC-157 or other research peptides shipped to New York?
Four of the five ship to New York as compounded injectables under a patient-specific prescription: BPC-157, TB-500, Epitalon and MOTS-c. KPV does not, because we compound these lines as injectables only. Each one’s own federal record is stated in its section above.
Why wasn’t New York in the first five state pages?
Sequencing, not law. The pilot covered five states first and New York was deliberately next in line. The research for this page surfaced no New York-specific published position on any of the ten product lines.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
